Guided Therapeutics (GTHP) 0.0012 $GTHP Guided
Post# of 273240
Posted On: 09/25/2016 1:18:18 PM
Guided Therapeutics (GTHP) 0.0012 $GTHP
Guided Therapeutics Receives Order for 7 LuViva(R) Advanced Cervical Scans and 4,000 Disposable Cervical Guides for Indonesia
BusinessWire - Wed Aug 31, 7:05AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), developer of the LuViva(R)Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care, today announced it has received an order for seven additional LuViva(R) Advanced Cervical Scans and 4,000 disposable Cervical Guides for Indonesia.
Guided Therapeutics Reports Second Quarter 2016 Financial Results; Year to Date Revenue Up 71% Over Same Period Last Year
BusinessWire - Wed Aug 17, 3:05PM CDT
--100th LuViva(R) Advanced Cervical Scan shipped in Q2
Smart Lighting Technology Emerging as Leading Segment of Multi Billion Dollar Clean Useable Energy Industry
PR Newswire - Tue Aug 16, 8:00AM CDT
The demand for energy-efficient solutions and products that included LED technology has received significant attention recently from companies, utilities and consumers looking to reduce their energy consumption use. As clean energy continues to trend upward in the United States and across the rest of the world, both federal and private investments fuel the sector's significant growth with enhanced research and development and latest innovations.
Guided Therapeutics Expanding Use of the LuViva(R) Advanced Cervical Scan in Bulgaria
BusinessWire - Mon Jun 13, 7:30AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP) announced today that it has received an order and payment for a third LuViva(R) Advanced Cervical Scan and 500 single-use disposable cervical guides for Bulgaria.
Guided Therapeutics Enters into LuViva(R) Advanced Cervical Scan License Agreement for China
BusinessWire - Tue Jun 07, 7:05AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has reached a licensing agreement with Shenghuo Medical, LLC, for exclusive sales and manufacturing rights of the LuViva(R) Advanced Cervical Scan for China and several additional Southeast Asian countries. Shenghuo brought Chinese investors into GTHP last year and currently owns the distribution rights to China.
Guided Therapeutics Reports Record First Quarter 2016 Results
BusinessWire - Thu May 19, 7:37AM CDT
--$262,000 of sales in 1Q 2016, a 106% increase from 2015
Guided Therapeutics Ships First LuViva(R) Advanced Cervical Scan for the Dominican Republic
BusinessWire - Wed May 11, 7:30AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today shipment of the first LuViva(R) Advanced Cervical Scan for the Dominican Republic.
Guided Therapeutics Expands LuViva(R) Advanced Cervical Scan Distribution in Latin America
BusinessWire - Tue Feb 09, 7:30AM CST
Guided Therapeutics, Inc. (OTCQB:GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that the company continues to expand in international markets with the signing of a distributor for the Dominican Republic for the LuViva(R) Advanced Cervical Scan.
2016 U.S. Tumor Marker Testing Market
M2 - Wed Feb 03, 8:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/mzjsp8/2016_u_s_tumor) has announced the addition of the "2016 U.S. Tumor Marker Testing Market: Supplier Shares by Test, Country Volume and Sales Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive Strategies, Emerging Opportunities" report to their offering. This new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the US cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion. Company Assessments - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics/Theradiag - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Eiken Chemical - Elitech Group - Epigenomics - Enterix/Clinical Genomics - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh For more information visit http://www.researchandmarkets.com/research/mz..._u_s_tumor
SQNM: 2.39 (-0.01), ENZ: 5.13 (-0.07), A: 46.61 (-0.06), DGX: 85.44 (-0.29), CPHD: 52.50 (unch), DHR: 77.59 (-0.08), HOLX: 38.45 (-0.33)
Guided Therapeutics' to Sell Five Additional LuViva(R) Advanced Cervical Scans to Nairobi County, Kenya for Cervical Cancer Screening Program
BusinessWire - Thu Jan 28, 7:30AM CST
Guided Therapeutics, Inc. (OTCQB: GTHP), a maker of a rapid and painless testing platform based on its patented biophotonic technology, today announced that Nairobi County Health Services Sector has agreed to purchase an additional five LuViva(R) Advanced Cervical Scans for use in the agency's cervical cancer screening program.
Guided Therapeutics Expects Significant Sales Growth in 2016
BusinessWire - Thu Jan 21, 8:49AM CST
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that the company expects to achieve a second consecutive quarter of record sales for the LuViva(R) Advanced Cervical Scan. The company also expects to close on an interim financing during the quarter.
Global Cancer Diagnostics 2016: Business Challenges, Emerging Technologies & Competitive Landscape
M2 - Tue Jan 19, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/xd2h9v/2016_new) has announced the addition of the "2016 New Frontiers in the Global Cancer Diagnostics: Business Challenges, Emerging Technologies, Competitive Landscape" report to their offering. The report is a new study of the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Companies Mentioned: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - (20 Others) For more information visit http://www.researchandmarkets.com/research/xd2h9v/2016_new
MYGN: 21.67 (+0.17), ENZ: 5.13 (-0.07), A: 46.61 (-0.06), CPHD: 52.50 (unch), DHR: 77.59 (-0.08), HOLX: 38.45 (-0.33)
Guided Therapeutics Achieves Record Quarterly Revenue
BusinessWire - Tue Jan 12, 8:08AM CST
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today fourth quarter sales revenue for the LuViva(R) Advanced Cervical Scan was the highest since the launch of the product.
Global Tumor Marker Testing Market Report - Analysis, Technologies, Strategies & Forecasts 2016
M2 - Tue Jan 12, 2:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/hsj9q6/2016_analysis_of) has announced the addition of the "2016 Analysis of the Global Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers" report to their offering. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. Benefits of this Report: - Identifies and evaluates major business opportunities emerging in the tumor marker market during the next ten years - Examines trends in the U.S., Europe and Japan - Reviews current and emerging tumor markers - Analyzes applications of emerging diagnostic technologies - Forecasts sales of major tumor markers by country and market segment - Profiles leading market players and potential entrants Technology Review: - Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and their potential applications for tumor marker testing - Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy Competitive Assessments: - Extensive strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D Worldwide Market Overview: - Estimated universe of laboratories performing tumor marker testing by country - Ten-year test volume and sales projections by country Business Opportunities and Strategic Recommendations: - Specific new product development opportunities with potentially significant market appeal during the next ten years - Design criteria for new products - Alternative market penetration strategies Contains 1,200 pages and 450 tables Companies Mentioned Include: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics/Theradiag - bioMerieux - Bio-Rad - CellSearch - Elitech Group - Enterix/Clinical Genomics - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Polymedco - PreMD - Qiagen - Targeted Diagnostics & Therapeutics - Thermo Fisher - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/hs...nalysis_of
ENZ: 5.13 (-0.07), A: 46.61 (-0.06), DHR: 77.59 (-0.08), HOLX: 38.45 (-0.33)
US Emerging Tumor Marker Testing Market 2016: Emerging Opportunities & Growth Strategies for Instrument & Reagent Suppliers
M2 - Mon Jan 04, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/43wzp4/2016_us_emerging) has announced the addition of the "US Emerging Tumor Marker Testing Market 2016: Emerging Opportunities and Growth Strategies for Instrument & Reagent Suppliers" report to their offering. This report is a comprehensive 620-page analysis of the US tumor marker testing market. The major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer are included. Types of Cancer Included: - Lung - Colorectal - Breast - Prostatic - Pancreatic - Leukemia - Lymphoma - Gastrointestinal - Bladder - Liver - Ovarian - Testicular - Oral - Skin - Others. Scope of the Report: - Five-year test volume and sales forecasts over for 40 tumor marker performed in US hospitals, commercial laboratories and physician offices. - Placements and installed base of automated and semi-automated analyzers used for tumor marker testing. - Current instrumentation technologies and feature comparison of leading analyzers. - Sales and market shares of leading suppliers. - Emerging diagnostic technologies and their potential market applications. - Product development opportunities. - Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. - Business opportunities and strategic recommendations for suppliers. Companies Included: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - (20 Others) For more information visit http://www.researchandmarkets.com/research/43...s_emerging
MYGN: 21.67 (+0.17), ENZ: 5.13 (-0.07), A: 46.61 (-0.06), CPHD: 52.50 (unch), DHR: 77.59 (-0.08), HOLX: 38.45 (-0.33)
Global Pap Smear/HPV Market Report - Analysis, Technologies, Opportunities & Forecasts 2016
M2 - Thu Dec 31, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/7drscd/2016_world_pap) has announced the addition of the "2016 World Pap Smear/HPV Market: Emerging Opportunities, Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Landscape--US, Europe (France, Germany, Italy, Spain, UK), Japan" report to their offering. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. This report presents a detailed analysis of the Pap Smear/HPV testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5-year test volume and sales forecasts by country and market segment. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Contains 243 pages and 7 tables Companies Mentioned: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics/Theradiag - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix/Clinical Genomics - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/7d..._world_pap
MYGN: 21.67 (+0.17), A: 46.61 (-0.06), DHR: 77.59 (-0.08), SQNM: 2.39 (-0.01), ENZ: 5.13 (-0.07), DGX: 85.44 (-0.29), CPHD: 52.50 (unch), HOLX: 38.45 (-0.33)
European Tumor Marker Testing Market Report - Analysis, Technologies, Opportunities & Forecasts 2016
M2 - Tue Dec 29, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/6qkltd/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the European Tumor Marker Testing Market: Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities" report to their offering. This unique report provides information not available from any other published source, including volume, sales, and leading supplier shares by test. This comprehensive five-country report identifies and evaluates major business opportunities emerging in the cancer diagnostics market during the next five years; examines trends in France, Germany, Italy, Spain, and the UK; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers. Contains 820 pages and 320 tables Companies Mentioned: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/6q...016_future
MYGN: 21.67 (+0.17), A: 46.61 (-0.06), DHR: 77.59 (-0.08), SQNM: 2.39 (-0.01), ENZ: 5.13 (-0.07), DGX: 85.44 (-0.29), CPHD: 52.50 (unch), HOLX: 38.45 (-0.33)
Global Tumor Markers Testing Market Report: Strategic Assessments of Major Suppliers & Emerging Opportunities 2016
M2 - Tue Dec 29, 9:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/nvkchc/2016_emerging) has announced the addition of the "2016 Emerging Opportunities in the Tumor Markers Testing Market: Strategic Assessments of Major Suppliers" report to their offering. This new 80-page report from the author provides insightful analyses of major current and emerging suppliers of tumor marker diagnostic instruments and reagents. The assessments include: - Sales - Product portfolios - Distribution tactics - Technological know-how - New products in R&D - Collaborative arrangements - Business strategies Contains 80 pages Companies Mentioned: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/nv...6_emerging
MYGN: 21.67 (+0.17), A: 46.61 (-0.06), DHR: 77.59 (-0.08), SQNM: 2.39 (-0.01), ENZ: 5.13 (-0.07), DGX: 85.44 (-0.29), CPHD: 52.50 (unch), HOLX: 38.45 (-0.33)
Emerging Opportunities in the Global Respiratory Diseases Diagnostic Testing Market 2016
M2 - Wed Dec 23, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/ljbdls/2016_emerging) has announced the addition of the "2016 Emerging Opportunities in the Global Respiratory Diseases Diagnostic Testing Market" report to their offering. This report presents detailed analysis of the Respiratory Disease market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on epidemiology and etiology are provided for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales forecasts by country and market segment, including: - Hospitals - Commercial/Private Labs - Physician Offices - Public Health Labs In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of respiratory disease diagnostic products, by test and country. Also, the report: - Examines market applications of Molecular Diagnostics, - Monoclonal Antibodies, Immunoassays, IT and other emerging technologies - Reviews features and operating characteristics of major analyzers used for respiratory disease testing; - Profiles key suppliers and potential market entrants developing innovative technologies and products - Analyzes emerging opportunities, alternative market penetration strategies, market entry barriers/risks, and strategic planning issues. Companies Mentioned: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - (20 Others) For more information visit http://www.researchandmarkets.com/research/lj...6_emerging
ENZ: 5.13 (-0.07), A: 46.61 (-0.06), CPHD: 52.50 (unch), DHR: 77.59 (-0.08), HOLX: 38.45 (-0.33)
2016 New Frontiers in the US Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape
M2 - Tue Dec 15, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/qj683t/2016_new) has announced the addition of the "2016 New Frontiers in the US Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape" report to their offering. "2016 New Frontiers in the US Cancer Diagnostics Market is a new study of the major business opportunities emerging in the U.S. cancer diagnostics market during the next five years. The report examines trends in the U.S. cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/qj683t/2016_new
MYGN: 21.67 (+0.17), A: 46.61 (-0.06), DHR: 77.59 (-0.08), SQNM: 2.39 (-0.01), ENZ: 5.13 (-0.07), DGX: 85.44 (-0.29), CPHD: 52.50 (unch), HOLX: 38.45 (-0.33)
Guided Therapeutics Receives Order for 7 LuViva(R) Advanced Cervical Scans and 4,000 Disposable Cervical Guides for Indonesia
BusinessWire - Wed Aug 31, 7:05AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), developer of the LuViva(R)Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care, today announced it has received an order for seven additional LuViva(R) Advanced Cervical Scans and 4,000 disposable Cervical Guides for Indonesia.
Guided Therapeutics Reports Second Quarter 2016 Financial Results; Year to Date Revenue Up 71% Over Same Period Last Year
BusinessWire - Wed Aug 17, 3:05PM CDT
--100th LuViva(R) Advanced Cervical Scan shipped in Q2
Smart Lighting Technology Emerging as Leading Segment of Multi Billion Dollar Clean Useable Energy Industry
PR Newswire - Tue Aug 16, 8:00AM CDT
The demand for energy-efficient solutions and products that included LED technology has received significant attention recently from companies, utilities and consumers looking to reduce their energy consumption use. As clean energy continues to trend upward in the United States and across the rest of the world, both federal and private investments fuel the sector's significant growth with enhanced research and development and latest innovations.
Guided Therapeutics Expanding Use of the LuViva(R) Advanced Cervical Scan in Bulgaria
BusinessWire - Mon Jun 13, 7:30AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP) announced today that it has received an order and payment for a third LuViva(R) Advanced Cervical Scan and 500 single-use disposable cervical guides for Bulgaria.
Guided Therapeutics Enters into LuViva(R) Advanced Cervical Scan License Agreement for China
BusinessWire - Tue Jun 07, 7:05AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has reached a licensing agreement with Shenghuo Medical, LLC, for exclusive sales and manufacturing rights of the LuViva(R) Advanced Cervical Scan for China and several additional Southeast Asian countries. Shenghuo brought Chinese investors into GTHP last year and currently owns the distribution rights to China.
Guided Therapeutics Reports Record First Quarter 2016 Results
BusinessWire - Thu May 19, 7:37AM CDT
--$262,000 of sales in 1Q 2016, a 106% increase from 2015
Guided Therapeutics Ships First LuViva(R) Advanced Cervical Scan for the Dominican Republic
BusinessWire - Wed May 11, 7:30AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today shipment of the first LuViva(R) Advanced Cervical Scan for the Dominican Republic.
Guided Therapeutics Expands LuViva(R) Advanced Cervical Scan Distribution in Latin America
BusinessWire - Tue Feb 09, 7:30AM CST
Guided Therapeutics, Inc. (OTCQB:GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that the company continues to expand in international markets with the signing of a distributor for the Dominican Republic for the LuViva(R) Advanced Cervical Scan.
2016 U.S. Tumor Marker Testing Market
M2 - Wed Feb 03, 8:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/mzjsp8/2016_u_s_tumor) has announced the addition of the "2016 U.S. Tumor Marker Testing Market: Supplier Shares by Test, Country Volume and Sales Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive Strategies, Emerging Opportunities" report to their offering. This new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the US cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion. Company Assessments - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics/Theradiag - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Eiken Chemical - Elitech Group - Epigenomics - Enterix/Clinical Genomics - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh For more information visit http://www.researchandmarkets.com/research/mz..._u_s_tumor
SQNM: 2.39 (-0.01), ENZ: 5.13 (-0.07), A: 46.61 (-0.06), DGX: 85.44 (-0.29), CPHD: 52.50 (unch), DHR: 77.59 (-0.08), HOLX: 38.45 (-0.33)
Guided Therapeutics' to Sell Five Additional LuViva(R) Advanced Cervical Scans to Nairobi County, Kenya for Cervical Cancer Screening Program
BusinessWire - Thu Jan 28, 7:30AM CST
Guided Therapeutics, Inc. (OTCQB: GTHP), a maker of a rapid and painless testing platform based on its patented biophotonic technology, today announced that Nairobi County Health Services Sector has agreed to purchase an additional five LuViva(R) Advanced Cervical Scans for use in the agency's cervical cancer screening program.
Guided Therapeutics Expects Significant Sales Growth in 2016
BusinessWire - Thu Jan 21, 8:49AM CST
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that the company expects to achieve a second consecutive quarter of record sales for the LuViva(R) Advanced Cervical Scan. The company also expects to close on an interim financing during the quarter.
Global Cancer Diagnostics 2016: Business Challenges, Emerging Technologies & Competitive Landscape
M2 - Tue Jan 19, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/xd2h9v/2016_new) has announced the addition of the "2016 New Frontiers in the Global Cancer Diagnostics: Business Challenges, Emerging Technologies, Competitive Landscape" report to their offering. The report is a new study of the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Companies Mentioned: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - (20 Others) For more information visit http://www.researchandmarkets.com/research/xd2h9v/2016_new
MYGN: 21.67 (+0.17), ENZ: 5.13 (-0.07), A: 46.61 (-0.06), CPHD: 52.50 (unch), DHR: 77.59 (-0.08), HOLX: 38.45 (-0.33)
Guided Therapeutics Achieves Record Quarterly Revenue
BusinessWire - Tue Jan 12, 8:08AM CST
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today fourth quarter sales revenue for the LuViva(R) Advanced Cervical Scan was the highest since the launch of the product.
Global Tumor Marker Testing Market Report - Analysis, Technologies, Strategies & Forecasts 2016
M2 - Tue Jan 12, 2:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/hsj9q6/2016_analysis_of) has announced the addition of the "2016 Analysis of the Global Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers" report to their offering. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. Benefits of this Report: - Identifies and evaluates major business opportunities emerging in the tumor marker market during the next ten years - Examines trends in the U.S., Europe and Japan - Reviews current and emerging tumor markers - Analyzes applications of emerging diagnostic technologies - Forecasts sales of major tumor markers by country and market segment - Profiles leading market players and potential entrants Technology Review: - Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and their potential applications for tumor marker testing - Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy Competitive Assessments: - Extensive strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D Worldwide Market Overview: - Estimated universe of laboratories performing tumor marker testing by country - Ten-year test volume and sales projections by country Business Opportunities and Strategic Recommendations: - Specific new product development opportunities with potentially significant market appeal during the next ten years - Design criteria for new products - Alternative market penetration strategies Contains 1,200 pages and 450 tables Companies Mentioned Include: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics/Theradiag - bioMerieux - Bio-Rad - CellSearch - Elitech Group - Enterix/Clinical Genomics - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Polymedco - PreMD - Qiagen - Targeted Diagnostics & Therapeutics - Thermo Fisher - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/hs...nalysis_of
ENZ: 5.13 (-0.07), A: 46.61 (-0.06), DHR: 77.59 (-0.08), HOLX: 38.45 (-0.33)
US Emerging Tumor Marker Testing Market 2016: Emerging Opportunities & Growth Strategies for Instrument & Reagent Suppliers
M2 - Mon Jan 04, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/43wzp4/2016_us_emerging) has announced the addition of the "US Emerging Tumor Marker Testing Market 2016: Emerging Opportunities and Growth Strategies for Instrument & Reagent Suppliers" report to their offering. This report is a comprehensive 620-page analysis of the US tumor marker testing market. The major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer are included. Types of Cancer Included: - Lung - Colorectal - Breast - Prostatic - Pancreatic - Leukemia - Lymphoma - Gastrointestinal - Bladder - Liver - Ovarian - Testicular - Oral - Skin - Others. Scope of the Report: - Five-year test volume and sales forecasts over for 40 tumor marker performed in US hospitals, commercial laboratories and physician offices. - Placements and installed base of automated and semi-automated analyzers used for tumor marker testing. - Current instrumentation technologies and feature comparison of leading analyzers. - Sales and market shares of leading suppliers. - Emerging diagnostic technologies and their potential market applications. - Product development opportunities. - Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. - Business opportunities and strategic recommendations for suppliers. Companies Included: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - (20 Others) For more information visit http://www.researchandmarkets.com/research/43...s_emerging
MYGN: 21.67 (+0.17), ENZ: 5.13 (-0.07), A: 46.61 (-0.06), CPHD: 52.50 (unch), DHR: 77.59 (-0.08), HOLX: 38.45 (-0.33)
Global Pap Smear/HPV Market Report - Analysis, Technologies, Opportunities & Forecasts 2016
M2 - Thu Dec 31, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/7drscd/2016_world_pap) has announced the addition of the "2016 World Pap Smear/HPV Market: Emerging Opportunities, Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Landscape--US, Europe (France, Germany, Italy, Spain, UK), Japan" report to their offering. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. This report presents a detailed analysis of the Pap Smear/HPV testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5-year test volume and sales forecasts by country and market segment. The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Contains 243 pages and 7 tables Companies Mentioned: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics/Theradiag - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix/Clinical Genomics - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/7d..._world_pap
MYGN: 21.67 (+0.17), A: 46.61 (-0.06), DHR: 77.59 (-0.08), SQNM: 2.39 (-0.01), ENZ: 5.13 (-0.07), DGX: 85.44 (-0.29), CPHD: 52.50 (unch), HOLX: 38.45 (-0.33)
European Tumor Marker Testing Market Report - Analysis, Technologies, Opportunities & Forecasts 2016
M2 - Tue Dec 29, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/6qkltd/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the European Tumor Marker Testing Market: Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities" report to their offering. This unique report provides information not available from any other published source, including volume, sales, and leading supplier shares by test. This comprehensive five-country report identifies and evaluates major business opportunities emerging in the cancer diagnostics market during the next five years; examines trends in France, Germany, Italy, Spain, and the UK; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers. Contains 820 pages and 320 tables Companies Mentioned: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/6q...016_future
MYGN: 21.67 (+0.17), A: 46.61 (-0.06), DHR: 77.59 (-0.08), SQNM: 2.39 (-0.01), ENZ: 5.13 (-0.07), DGX: 85.44 (-0.29), CPHD: 52.50 (unch), HOLX: 38.45 (-0.33)
Global Tumor Markers Testing Market Report: Strategic Assessments of Major Suppliers & Emerging Opportunities 2016
M2 - Tue Dec 29, 9:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/nvkchc/2016_emerging) has announced the addition of the "2016 Emerging Opportunities in the Tumor Markers Testing Market: Strategic Assessments of Major Suppliers" report to their offering. This new 80-page report from the author provides insightful analyses of major current and emerging suppliers of tumor marker diagnostic instruments and reagents. The assessments include: - Sales - Product portfolios - Distribution tactics - Technological know-how - New products in R&D - Collaborative arrangements - Business strategies Contains 80 pages Companies Mentioned: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/nv...6_emerging
MYGN: 21.67 (+0.17), A: 46.61 (-0.06), DHR: 77.59 (-0.08), SQNM: 2.39 (-0.01), ENZ: 5.13 (-0.07), DGX: 85.44 (-0.29), CPHD: 52.50 (unch), HOLX: 38.45 (-0.33)
Emerging Opportunities in the Global Respiratory Diseases Diagnostic Testing Market 2016
M2 - Wed Dec 23, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/ljbdls/2016_emerging) has announced the addition of the "2016 Emerging Opportunities in the Global Respiratory Diseases Diagnostic Testing Market" report to their offering. This report presents detailed analysis of the Respiratory Disease market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on epidemiology and etiology are provided for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales forecasts by country and market segment, including: - Hospitals - Commercial/Private Labs - Physician Offices - Public Health Labs In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of respiratory disease diagnostic products, by test and country. Also, the report: - Examines market applications of Molecular Diagnostics, - Monoclonal Antibodies, Immunoassays, IT and other emerging technologies - Reviews features and operating characteristics of major analyzers used for respiratory disease testing; - Profiles key suppliers and potential market entrants developing innovative technologies and products - Analyzes emerging opportunities, alternative market penetration strategies, market entry barriers/risks, and strategic planning issues. Companies Mentioned: - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - (20 Others) For more information visit http://www.researchandmarkets.com/research/lj...6_emerging
ENZ: 5.13 (-0.07), A: 46.61 (-0.06), CPHD: 52.50 (unch), DHR: 77.59 (-0.08), HOLX: 38.45 (-0.33)
2016 New Frontiers in the US Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape
M2 - Tue Dec 15, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/qj683t/2016_new) has announced the addition of the "2016 New Frontiers in the US Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape" report to their offering. "2016 New Frontiers in the US Cancer Diagnostics Market is a new study of the major business opportunities emerging in the U.S. cancer diagnostics market during the next five years. The report examines trends in the U.S. cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/qj683t/2016_new
MYGN: 21.67 (+0.17), A: 46.61 (-0.06), DHR: 77.59 (-0.08), SQNM: 2.39 (-0.01), ENZ: 5.13 (-0.07), DGX: 85.44 (-0.29), CPHD: 52.50 (unch), HOLX: 38.45 (-0.33)
(0)
(0)Scroll down for more posts ▼